Sfoglia per AUTORE
NERI A
Collezione ASL Cuneo 1
Items : 2
High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 - VERITAS study. in Haematologica / Haematologica. 2023 Aug 1;108(8):2091-2100. doi: 10.3324/haematol.2022.282116.
2023
AOU Alessandria
AO Cuneo
AOU Città della Salute di Torino
AO Ordine Mauriziano
ASL Cuneo 1
AOU Novara
Fazi P; Vignetti M; Piciocchi A; Cuneo A; Foà R; Guarini A; Nanni M; Neri A; De Propris MS; De Novi LA; Visentin A; Vitale C; Albano F; Molinari MC; Pietrasanta D; Mattiello V; Liberati AM; Giordano A; Gottardi D; Patrizi VB; Galieni P; Musuraca G; Deodato M; Arcari A; Tani M; Levato L; Marchetti M; Massaia M; Rigolin GM; et alii...
Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study. in Cancers / Cancers (Basel). 2021 Dec 31;14(1):207. doi: 10.3390/cancers14010207.
2021
AO Cuneo
ASL Cuneo 1
AOU Città della Salute di Torino
AO Ordine Mauriziano
AOU Alessandria
AOU Novara
Piciocchi A; Cuneo A; Foà R; Fazi P; Neri A; Guarini A; Rigolin GM; Nanni M; De Propris MS; Della Starza I; Raponi S; Del Giudice I; Murru R; Ruocco V; Ibatici A; Varettoni M; Laurenti L; Chiarenza A; Zinzani PL; Gentile M; Molinari A; Gozzetti A; Tani M; Musuraca G; Gottardi D; Re F; Orsucci L; Liberati AM; Ilariucci F; et alii...